Physician profile

Heather A Morphy

Family Medicine · Pasadena, MD

NPI 1912908294

$731.71

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$440.77

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $270.74 2019-2024 Ozempic, Rybelsus, Wegovy
Lilly USA, LLC $145.97 2020-2024 Mounjaro, Zepbound
Astrazeneca Pharmaceuticals LP $126.03 2019-2024 Farxiga, Airsupra
Axsome Therapeutics, INC. $117.87 2024 Auvelity
Merck Sharp & Dohme LLC $31.58 2019-2024 Proquad, Gardasil, Gardasil 9
Astellas Pharma US INC $21.48 2024 Veozah
Exact Sciences Corporation $18.04 2024 Cologuard Collection Kit

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Heather A Morphy

$731.71

in general payments reported 2019-2025

Years
2019-2024
Top company
Novo Nordisk INC

https://glasscript.com/doctor/358988/heather-a-morphy

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.